Trial Profile
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ACE-536 in Healthy Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Luspatercept (Primary)
- Indications Osteoporosis
- Focus Adverse reactions
- Sponsors Acceleron Pharma
- 29 Oct 2014 New trial record